Holen Sie sich die Stockscreener-App
4.98
9.12%
-0.50
Handel nachbörslich:
5.00
0.02
+0.40%
Schlusskurs vom Vortag:
$5.48
Offen:
$4.89
24-Stunden-Volumen:
128.18K
Relative Volume:
6.99
Marktkapitalisierung:
$209.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.58%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.75
$5.0328
1-Wochen-Bereich:
$4.75
$6.20
52-Wochen-Spanne:
$4.50
$6.2324
Tuhura Biosciences Inc Stock (HURA) Company Profile
Firmenname
Tuhura Biosciences Inc
Sektor
Branche
Telefon
(858) 350-4364
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 150, SAN DIEGO
Tuhura Biosciences Inc Aktie (HURA) Neueste Nachrichten
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - AccessWire
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event - AccessWire
TuHURA Biosciences finalizes merger, sets Phase 3 trial - Investing.com India
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 - PR Newswire
HURA Stock Price and Chart — NASDAQ:HURA - TradingView
TuHURA Biosciences finalizes merger, sets Phase 3 trial By Investing.com - Investing.com South Africa
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics - Yahoo Finance
Lowenstein Represents Kintara Therapeutics in Merger with TuHURA Biosciences - Lowenstein Sandler LLP
Kintara Therapeutics Announces Stock Split Amid Merger - TipRanks
Kintara approves reverse stock split, rebrands as TuHURA Biosciences - Investing.com India
Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger - TipRanks
Kintara approves 1-for-35 reverse stock split before merger - Investing.com
Kintara approves 1-for-35 reverse stock split before merger By Investing.com - Investing.com South Africa
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 - StockTitan
Kintara approves reverse stock split, rebrands as TuHURA Biosciences By Investing.com - Investing.com Australia
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - Quantisnow
Kintara amends CVR issuance terms ahead of TuHURA merger By Investing.com - Investing.com Canada
Kintara amends CVR issuance terms ahead of TuHURA merger - Investing.com India
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 - StockTitan
Kintara stock climbs 10% on TuHURA merger update (NASDAQ:KTRA) - Seeking Alpha
Stockholders Fail to Approve Proposal to Reincorporate Nevada Corporation in Delaware - The National Law Review
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update - StockTitan
Kintara shareholders approve key proposals; Charter change fails By Investing.com - Investing.com UK
Kintara shareholders approve key proposals; Charter change fails - Investing.com
Kintara Therapeutics modifies merger terms with TuHURA Biosciences - Investing.com
Kintara Urges Shareholder Votes for TuHURA Biosciences Merger - TipRanks
Kintara delays special meeting vote on key proposals By Investing.com - Investing.com South Africa
Kineta, Inc Transitioning from Nasdaq to OTC Markets - StockTitan
Kintara Therapeutics Seeks Approval for Key Merger with TuHURA Biosciences - TipRanks
Kintara Therapeutics Advances with TuHURA Merger and Trials - TipRanks
Kintara urges stockholder vote for TuHURA merger - Investing.com
Kintara Therapeutics announces special meeting details By Investing.com - Investing.com Australia
Kintara Therapeutics: Clinical Trial Resumes Amid Merger Uncertainties - TipRanks
Kintara Therapeutics restructures share designations - Investing.com
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor - PR Newswire
Kintara and TuHURA announce merger and clinical progress - Investing.com
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carci - PR Newswire
Laurel Lee from Florida's 15th district invests in TuHURA Biosciences By Investing.com - Investing.com
Kintara Therapeutics Reports Improved Q3 Results - TipRanks
Wolfe Research cuts Warner Bros Discovery stock to underperform By Investing.com - Investing.com Nigeria
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc.KTRA - PR Newswire
Kintara and TuHURA in merger deal to advance oncology pipeline - Pharmaceutical Technology
Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today? - InvestorPlace
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab - PR Newswire
Kintara Therapeutics And TuHURA Biosciences To Merge - Contract Pharma
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer - PR Newswire
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement - PR Newswire
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study - PR Newswire
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting - PR Newswire
2 small biotechs morph to work on oncology together - Fierce Biotech
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer - PR Newswire
Finanzdaten der Tuhura Biosciences Inc-Aktie (HURA)
Es liegen keine Finanzdaten für Tuhura Biosciences Inc (HURA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):